Benzinga | Apr 27, 2021 06:34AM EDT

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $50

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $57 to $50.